BI3 -- Biogen Idec's Innovation Incubator.
- Published in:
- 2007
- Publication type:
- Product Review
Works matching DE "BIOGEN Inc. (2003- )"
Results: 92
1
2
Search and Deploy.
- Published in:
- Bio-IT World, 2006, v. 5, n. 8, p. 24
- By:
- Publication type:
- Article
3
News Blast.
- Published in:
- Bio-IT World, 2006, v. 5, n. 6, p. 30
- Publication type:
- Article
4
The Other Guy's Shoes.
- Published in:
- Bio-IT World, 2005, v. 4, n. 1, p. 10
- By:
- Publication type:
- Article
5
News Blast.
- Published in:
- Bio-IT World, 2004, v. 3, n. 12, p. 8
- Publication type:
- Article
6
News Blast.
- Published in:
- Bio-IT World, 2004, v. 3, n. 11, p. 10
- Publication type:
- Article
7
Two Paths, One Molecule.
- Published in:
- Bio-IT World, 2004, v. 3, n. 2, p. 14
- By:
- Publication type:
- Article
8
Impact of recent IP caselaw on biomarkers and personalized medicine.
- Published in:
- Journal of Commercial Biotechnology, 2011, v. 17, n. 2, p. 191, doi. 10.1057/jcb.2010.36
- By:
- Publication type:
- Article
9
Medicines Australia clamps down on code breakers.
- Published in:
- Australian Journal of Pharmacy, 2011, v. 92, n. 1089, p. 50
- Publication type:
- Article
10
Biomedical briefing.
- Published in:
- Nature Medicine, 2014, v. 20, n. 7, p. 696, doi. 10.1038/nm0714-696
- Publication type:
- Article
11
The clot thickens for long-lasting drugs that stop hemophilia short.
- Published in:
- Nature Medicine, 2013, v. 19, n. 2, p. 121, doi. 10.1038/nm0213-121
- By:
- Publication type:
- Article
12
Drug ads move online, creating a web of regulatory challenges.
- Published in:
- Nature Medicine, 2010, v. 16, n. 1, p. 22, doi. 10.1038/nm0110-22
- By:
- Publication type:
- Article
13
Tysabri's return draws cautious optimism.
- Published in:
- American Journal of Health-System Pharmacy, 2006, v. 63, n. 15, p. 1388, doi. 10.2146/news050092
- By:
- Publication type:
- Article
14
News Briefs.
- Published in:
- American Journal of Health-System Pharmacy, 2004, v. 61, n. 3, p. 234, doi. 10.1093/ajhp/61.3.234
- Publication type:
- Article
15
Antibody drugs for Alzheimer's show glimmers of promise.
- Published in:
- Nature, 2015, v. 523, n. 7562, p. 509, doi. 10.1038/nature.2015.18031
- By:
- Publication type:
- Article
16
Drug that boosts nerve signals offers hope for multiple sclerosis.
- Published in:
- Nature, 2015, v. 520, n. 7548, p. 417, doi. 10.1038/520417a
- By:
- Publication type:
- Article
17
Business digest.
- Published in:
- Chemistry & Industry, 2013, v. 77, n. 1, p. 19
- Publication type:
- Article
18
People.
- Published in:
- Chemistry & Industry, 2011, n. 3, p. 16
- Publication type:
- Article
19
Science in brief.
- Published in:
- Chemistry & Industry, 2009, n. 19, p. 10
- Publication type:
- Article
20
Tysabri drug rights battle to end.
- Published in:
- Chemistry & Industry, 2009, n. 18, p. 6
- By:
- Publication type:
- Article
21
Elan and Biogen square up for fight over Tysabri.
- Published in:
- Chemistry & Industry, 2009, n. 16, p. 5
- By:
- Publication type:
- Article
22
Cell culture grows capacity.
- Published in:
- Chemistry & Industry, 2005, n. 20, p. 21
- Publication type:
- Article
23
Tysabri may make a comeback but with limited market potential.
- Published in:
- Chemistry & Industry, 2005, n. 17, p. 6
- By:
- Publication type:
- Article
24
News in brief.
- Published in:
- Chemistry & Industry, 2005, n. 16, p. 6
- Publication type:
- Article
25
News in brief.
- Published in:
- Chemistry & Industry, 2005, n. 5, p. 4
- Publication type:
- Article
26
News.
- Published in:
- Chemistry & Industry, 2004, n. 23, p. 6
- Publication type:
- Article
27
BUSINESS AND PEOPLE UPDATE.
- Published in:
- Applied Clinical Trials, 2007, v. 16, n. 2, p. 74
- Publication type:
- Article
28
News.
- Published in:
- Clinical Infectious Diseases, 2011, v. 52, n. 6, p. i, doi. 10.1093/cid/cir059
- Publication type:
- Article
29
ADDITIONAL DEVELOPMENTS-PATENT: BIOGENIDEC MA INC. v. TRUSTEES OF COLUMBIA UNIVERSITY 2004 WL 1839726 (D. Mass. Aug. 13, 2004).
- Published in:
- Berkeley Technology Law Journal, 2005, v. 20, n. 1, p. 173
- Publication type:
- Article
30
The comeback kid: TYSABRI now FDA approved for Crohn disease.
- Published in:
- 2008
- By:
- Publication type:
- journal article
31
Drug makers and NIH team up to find and validate targets.
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 4, p. 241, doi. 10.1038/nrd4293
- By:
- Publication type:
- Article
32
Deal watch: Biogen and Amicus to pursue genetically validated Parkinson's disease target.
- Published in:
- Nature Reviews Drug Discovery, 2013, v. 12, n. 11, p. 819, doi. 10.1038/nrd4166
- By:
- Publication type:
- Article
33
Big expectations for Biogen's small MS drug.
- Published in:
- Nature Reviews Drug Discovery, 2013, v. 12, n. 5, p. 333, doi. 10.1038/nrd4087
- Publication type:
- Article
34
Deal watch: Biogen acquires Stromedix to pursue novel fibrosis therapy.
- Published in:
- Nature Reviews Drug Discovery, 2012, v. 11, n. 4, p. 260, doi. 10.1038/nrd3708
- By:
- Publication type:
- Article
35
Deal watch: High hopes for oral SYK inhibitor in rheumatoid arthritis.
- Published in:
- Nature Reviews Drug Discovery, 2012, v. 11, n. 1, p. 10, doi. 10.1038/nrd3631
- By:
- Publication type:
- Article
36
News in brief.
- Published in:
- Nature Reviews Drug Discovery, 2011, v. 10, n. 9, p. 647, doi. 10.1038/nrd3547
- Publication type:
- Article
37
Trial watch: Phase III success for Biogen's oral multiple sclerosis therapy.
- Published in:
- Nature Reviews Drug Discovery, 2011, v. 10, n. 6, p. 404, doi. 10.1038/nrd3465
- Publication type:
- Article
38
Patent watch.
- Published in:
- Nature Reviews Drug Discovery, 2010, v. 9, n. 7, p. 508, doi. 10.1038/nrd3218
- By:
- Publication type:
- Article
39
News in brief.
- Published in:
- Nature Reviews Drug Discovery, 2010, v. 9, n. 4, p. 259, doi. 10.1038/nrd3156
- Publication type:
- Article
40
News in brief.
- Published in:
- Nature Reviews Drug Discovery, 2007, v. 6, n. 11, p. 858, doi. 10.1038/nrd2457
- Publication type:
- Article
41
Lack of descriptive support results in no interference-in-fact.
- Published in:
- Nature Reviews Drug Discovery, 2004, v. 3, n. 3, p. 196, doi. 10.1038/nrd1339
- Publication type:
- Article
42
NEWS IN BRIEF.
- Published in:
- Nature Reviews Drug Discovery, 2004, v. 3, n. 3, p. 194
- Publication type:
- Article
43
Users Fear that Lymphoma Drugs Will Disappear.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2007, v. 99, n. 7, p. 498, doi. 10.1093/jnci/djk155
- By:
- Publication type:
- Article
44
For AD, Non-Pharma Efforts Becoming More Critical.
- Published in:
- Applied Clinical Trials, 2019, v. 28, n. 5, p. 2
- By:
- Publication type:
- Article
45
Biogen Idec restructures, sharpens neurology focus.
- Published in:
- Nature Biotechnology, 2011, v. 29, n. 1, p. 7, doi. 10.1038/nbt0111-7
- By:
- Publication type:
- Article
46
Novartis eyes oral MS drug as potential blockbuster.
- Published in:
- Nature Biotechnology, 2010, v. 28, n. 11, p. 1135, doi. 10.1038/nbt1110-1135
- By:
- Publication type:
- Article
47
People.
- Published in:
- Nature Biotechnology, 2010, v. 28, n. 8, p. 876, doi. 10.1038/nbt0810-876
- Publication type:
- Article
48
How Tysabri survived.
- Published in:
- 2009
- By:
- Publication type:
- Opinion
49
Tysabri's troubles return.
- Published in:
- Nature Biotechnology, 2008, v. 26, n. 10, p. 1061, doi. 10.1038/nbt1008-1061
- By:
- Publication type:
- Article
50
Start-ups weigh benefits of corporate incubators.
- Published in:
- Nature Biotechnology, 2008, v. 26, n. 3, p. 254, doi. 10.1038/nbt0308-254
- By:
- Publication type:
- Article